In addition, apatinib not only effectively inhibited tumor growth and angiogenesis in liver cancer but also induced NK cell activation, increased levels of interferon-γ, and decreased levels of tumor necrosis factor-α and interleukin-6, suggesting the potential benefit of combination therapy with PD-1 blockade and apatinib in liver cancer (90). Here, PDCD1 is linked to liver cancer.